These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37788655)

  • 1. Recent Developments in the Treatment of Pancreatic Cancer.
    Paulino J; Mansinho H
    Acta Med Port; 2023 Oct; 36(10):670-678. PubMed ID: 37788655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
    Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
    Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
    Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Treatment for Pancreatic Cancer.
    Raufi AG; Manji GA; Chabot JA; Bates SE
    Semin Oncol; 2019 Feb; 46(1):19-27. PubMed ID: 30630600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria.
    Bolm L; Pisuchpen N; Qadan M; Kambadakone A; Sondermann S; Mueller K; Petruch N; May K; Zelga P; Nebbia M; Michelakos T; Baba T; Roldan J; Harrison JM; Honselmann KC; Keck T; Lillemoe KD; Ferrone CR; Wellner UF; Fernandez-Del Castillo C
    Ann Surg; 2022 Aug; 276(2):215-221. PubMed ID: 36036988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The Clinical Efficacy of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Carcinoma--Report of Two Cases Treated by Curative Pancreatectomy with Portal Vein Resection after Neoadjuvant Chemotherapy].
    Imamura T; Ikoma H; Morimura R; Hatakeyama T; Kosuga T; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Otsuji E
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2379-81. PubMed ID: 26805370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis.
    Brown ZJ; Heh V; Labiner HE; Brock GN; Ejaz A; Dillhoff M; Tsung A; Pawlik TM; Cloyd JM
    Br J Surg; 2022 Dec; 110(1):34-42. PubMed ID: 36346716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Borderline resectable pancreatic cancer.
    Hackert T; Ulrich A; Büchler MW
    Cancer Lett; 2016 Jun; 375(2):231-237. PubMed ID: 26970276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery.
    Kitano Y; Inoue Y; Takeda T; Oba A; Ono Y; Sato T; Ito H; Ozaka M; Sasaki T; Sasahira N; Baba H; Takahashi Y
    Ann Surg Oncol; 2023 Aug; 30(8):5093-5102. PubMed ID: 37140750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population.
    Walpole I; Lee B; Shapiro J; Thomson B; Lipton L; Ananda S; Usatoff V; Mclachlan SA; Knowles B; Fox A; Wong R; Cooray P; Burge M; Clarke K; Pattison S; Nikfarjam M; Tebbutt N; Harris M; Nagrial A; Zielinski R; Chee CE; Gibbs P
    Asia Pac J Clin Oncol; 2023 Feb; 19(1):214-225. PubMed ID: 35831999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist's Perspective.
    de Jesus VHF; Riechelmann RP
    Cancer Control; 2023; 30():10732748231173212. PubMed ID: 37115533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection].
    Ridwelski K; Meyer F; Schmidt U; Lippert H
    Zentralbl Chir; 2005 Aug; 130(4):353-61. PubMed ID: 16103961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma.
    Zhang B; Lee GC; Qadan M; Fong ZV; Mino-Kenudson M; Desphande V; Malleo G; Maggino L; Marchegiani G; Salvia R; Scarpa A; Luchini C; De Gregorio L; Ferrone CR; Warshaw AL; Lillemoe KD; Bassi C; Castillo CF
    Ann Surg; 2021 Aug; 274(2):e134-e142. PubMed ID: 31851002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use.
    Rau BM; Moritz K; Schuschan S; Alsfasser G; Prall F; Klar E
    Surgery; 2012 Sep; 152(3 Suppl 1):S103-11. PubMed ID: 22766366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review.
    Datta J; Willobee BA; Ryon EL; Shah MM; Drebin JA; Kooby DA; Merchant NB
    JAMA Surg; 2021 May; 156(5):489-495. PubMed ID: 33533898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer.
    Klaiber U; Schnaidt ES; Hinz U; Gaida MM; Heger U; Hank T; Strobel O; Neoptolemos JP; Mihaljevic AL; Büchler MW; Hackert T
    Ann Surg; 2021 Jan; 273(1):154-162. PubMed ID: 30921051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma.
    Eid M; Ostřížková L; Kunovský L; Brančíková D; Kala Z; Hlavsa J; Janeček P; Kosíková I; Blažková M; Slabý O; Mayer J
    Neoplasma; 2021 Jan; 68(1):1-9. PubMed ID: 32880468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma.
    Tesfaye AA; Philip PA
    Clin Adv Hematol Oncol; 2019 Jan; 17(1):54-63. PubMed ID: 30843899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.